Recursion Announces Proposed Offering of Class A Common Stock
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: GlobeNewswire
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. The shares will be offered by Recursion pursuant
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Announces Pricing of $200 Million Public Offering of Class A Common StockGlobeNewswire
- Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $17.00 price target on the stock.MarketBeat
- Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data [Yahoo! Finance]Yahoo! Finance
- Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic DataBusiness Wire
RXRX
Earnings
- 5/9/24 - Beat
RXRX
Sec Filings
- 6/28/24 - Form 4
- 6/27/24 - Form 4
- 6/27/24 - Form 144
- RXRX's page on the SEC website